Identifying and quantifying impurities are essential steps in pharmaceutical development, with impurity reference standards (IRSs) playing a vital role.
In the absence of detailed regulatory guidance, we have incorporated expert opinions and analysis to recommend best practices for determining the appropriate level of IRS characterisation across a range of common applications.
